Opioid Equianalgesic Tables: Are They All Equally Dangerous?

Journal of Pain and Symptom Management

Volumn 38, Issue 3, 2009, Pages 409-417

  Shaheen, Philip E ^a   Walsh, Declan ^a   Lasheen, Wael ^a   Davis, Mellar P ^a   Lagman, Ruth L ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

analgesics; cancer pain; dosing; equianalgesia; Opioids

Indexed keywords

CODEINE; DOLPHINE; FENTANYL; HYDROMORPHONE; LEVORPHANOL; METHADONE; MORPHINE; MORPHINE SULFATE; OPIATE; ORAMORPH SR; OXYCODONE; PETHIDINE; UNCLASSIFIED DRUG;

ANALGESIA; ARTICLE; CANCER PAIN; CLINICAL PRACTICE; DOSE CALCULATION; DRUG PACKAGING; DRUG USE; MEDICAL EDUCATION; PRACTICE GUIDELINE; TEACHING;

ADMINISTRATION, ORAL; ANALGESICS, OPIOID; DRUG LABELING; GUIDELINES AS TOPIC; HUMANS; INFUSIONS, PARENTERAL; INTERNET; MORPHINE; PAIN; PATIENT EDUCATION AS TOPIC;

EID: 69549090030     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2009.06.004     Document Type: Article

References (31)

1. Davis M.P., and Walsh D. Epidemiology of cancer pain and factors influencing poor pain control. Am J Hosp Palliat Care 21 2 (2004) 137-142
2. Ripamonti C., Zecca E., and De Conno F. Pharmacological treatment of cancer pain: alternative routes of administration. Tumori 84 3 (1998) 289-300
3. Davis M., and Walsh D. Cancer pain syndromes. Eur J Palliat Care 7 6 (2000) 206-209
4. World Health Organization. Cancer pain relief. 2nd ed. (1996), World Health Organization, Geneva
5. Ventafridda V., Tamburini M., Caraceni A., De Conno F., and Naldi F. A validation study of the WHO method for cancer pain relief. Cancer 59 4 (1987) 850-856
6. Hanks G.W., and Forbes K. Opioid responsiveness. Acta Anaesthesiol Scand 41 1 Pt. 2 (1997) 154-158
7. Ballesteros M.F., Budnitz D.S., Sanford C.P., et al. Increase in deaths due to methadone in North Carolina. JAMA 290 1 (2003) 40
8. Burrows D.L., Hagardorn A.N., Harlan G.C., Wallen E.D., and Ferslew K.E. A fatal drug interaction between oxycodone and clonazepam. J Forensic Sci 48 3 (2003) 683-686
9. Gerber N., and Apseloff G. Death from morphine infusion during a sickle cell crisis. J Pediatr 123 2 (1993) 322-325
10. Mercadante S. Opioid rotation for cancer pain: rationale and clinical aspects. Cancer 86 9 (1999) 1856-1866
11. Walsh D., Davis M.P., Estfan B., et al. Opioid rotation prospective longitudinal study. [Abstract]. Proc Am Soc Clin Oncol 22 14S (2004) A8258
12. Enting R.H., Oldenmenger W.H., van der Rijt C.C., et al. A prospective study evaluating the response of patients with unrelieved cancer pain to parenteral opioids. Cancer 94 11 (2002) 3049-3056
13. Paulozzi L.J., Budnitz D.S., and Xi Y. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf 15 9 (2006) 618-627
14. Twycross R.G. A comparison of diamorphine-with-cocaine and methadone. [Letter]. Br J Clin Pharmacol 61 4 (1977) 691-693
15. Watanabe S., Belzile M., Kuehn N., Hanson J., and Bruera E. Capsules and suppositories of methadone for patients on high-dose opioids for cancer pain: clinical and economic considerations. Cancer Treat Rev 22 Suppl A (1996) 131-136
16. Hunt G., and Bruera E. Respiratory depression in a patient receiving oral methadone for cancer pain. J Pain Symptom Manage 10 5 (1995) 401-404
17. Regnard C., and Pelham A. Severe respiratory depression and sedation with transdermal fentanyl: four case studies. Palliat Med 17 8 (2003) 714-716
18. Anderson R., Saiers J.H., Abram S., and Schlicht C. Accuracy in equianalgesic dosing: conversion dilemmas. J Pain Symptom Manage 21 5 (2001) 397-406
19. Pereira J., Lawlor P., Vigano A., Dorgan M., and Bruera E. Equianalgesic dose ratios for opioids: a critical review and proposals for long-term dosing. J Pain Symptom Manage 22 2 (2001) 672-686
20. McCaffery M., and Ferrell B.R. Opioid analgesics: nurses' knowledge of doses and psychological dependence. J Nurs Staff Dev 8 2 (1992) 77-84
21. Ferrell B.R., and McCaffery M. Nurses' knowledge about equianalgesia and opioid dosing. Cancer Nurs 20 3 (1997) 201-212
22. Ripamonti C., De Conno F., Groff L., et al. Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: comparison of two clinical experiences. Ann Oncol 9 1 (1998) 79-83
23. Mercadante S., Casuccio A., Fulfaro F., et al. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol 19 11 (2001) 2898-2904
24. Cherny N.J., Chang V., Frager G., et al. Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and route of administration. Cancer 76 7 (1995) 1283-1293
25. Herndon C.M., Kalauokalani D.A., Cunningham A.J., Jackson II K.C., and Dunteman E.D. Anticipating and treating opioid-associated adverse effects. Expert Opin Drug Saf 2 3 (2003) 305-319
26. Ripamonti C., Groff L., Brunelli C., et al. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio?. J Clin Oncol 16 10 (1998) 3216-3221
27. Harris D.S., Mendelson J.E., Lin E.T., Upton R.A., and Jones R.T. Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality. Clin Pharmacokinet 43 5 (2004) 329-340
28. Thomsen A.B., Becker N., and Eriksen J. Opioid rotation in chronic non-malignant pain patients. A retrospective study. Acta Anaesthesiol Scand 43 9 (1999) 918-923
29. Davis M.P., Varga J., Dickerson, et al. Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy. Support Care Cancer 11 2 (2003) 84-92
30. Szeto H.H., Inturrisi C.E., Houde R., et al. Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure of cancer. Ann Intern Med 86 6 (1977) 738-741
31. De Luca A., and Coupar I.M. Insights into opioid action in the intestinal tract. Pharmacol Ther 69 2 (1996) 103-115